AbbVie (ABBV) Hits New 52-Week High; Stock Up 40% Yearly

AI Summary

AbbVie (ABBV) reached a new 52-week high, marking a 40% increase over the past year. Year-to-date, the stock has risen approximately 11%, outperforming the S&P 500's 8% gain. AbbVie trades at less than 18 times its estimated future earnings, below the S&P 500 average of 21. The company recently announced a $10.9 billion acquisition of Apogee Therapeutics, which will enhance its immunology portfolio, suggesting long-term growth potential amidst a strong earnings performance.